Biotech Values

[rjc2827]

This KRAS and EFGR testing is of interest to ONCY - (Oncolytics Biotech).

Oncolytics Biotech Link:
http://www.oncolyticsbiotech.com/

In general, Oncolytics' reovirus therapeutic works best against a wide variety of cancers with an activated Ras pathway. KRAS and activated EFGR are markers for an activated Ras pathway.

"Oncolytics announced in March 2009 that it had started patient enrolment in its U.S. Phase 2 clinical trial using intravenous administration of REOLYSIN® in combination with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) with K-RAS or EGFR-activated tumours."

rjc